A Kent and Medway Cancer Network (KMCN) audit of first-line treatment with cisplatin/pemetrexed (CisPem) in non squamous non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Letsa, I. [1 ]
Mikropoulos, C. [1 ]
Burcombe, R. [1 ]
Visioli, A. [1 ]
Sevitt, T. [1 ]
Cominos, M. [1 ]
Beesley, S. [1 ]
机构：
[1] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
来源：
LUNG CANCER | 2011年 / 71卷
关键词：
D O I：
10.1016/S0169-5002(11)70019-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [41] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
    Fennell, D. A.
    Summers, Y.
    Cadranel, J.
    Benepal, T.
    Christoph, D. C.
    Lal, R.
    Das, M.
    Maxwell, F.
    Visseren-Grul, C.
    Ferry, D.
    CANCER TREATMENT REVIEWS, 2016, 44 : 42 - 50
  • [43] Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
    Ryu, Rachel
    Ward, Kristina E.
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [44] Pemetrexed in second line of non-small cell lung cancer
    Earata, Fernando
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2008, 14 : S21 - S26
  • [45] A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC)
    Belani, Chandra Prakash
    Yamamoto, Nobuyuki
    Bondarenko, Igor
    Orlov, Sergey V.
    Tang, Jie
    Niethammer, Andreas G.
    Ingrosso, Antonella
    Kim, Sinil
    Scagliotti, Giorgio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] RETROSPECTIVE STUDY OF COMBINATION CHEMOTHERAPY WITH CISPLATIN PLUS PEMETREXED AS FIRST LINE THERAPY FOR ADVANCED NON-SMALL CELL NON-SQUAMOUS LUNG CANCER
    Inui, Toshiya
    Yokoyama, Takuma
    Takata, Saori
    Hirata, Aya
    Nishizawa, Tomotaka
    Hirukawa, Ichiro
    Wada, Hiroo
    Ishii, Haruyuki
    Takizawa, Hajime
    Goto, Hajime
    RESPIROLOGY, 2013, 18 : 149 - 149
  • [47] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with ImmuneCheckpoint Inhibitors
    Bylicki, Olivier
    Barazzutti, Helene
    Paleiron, Nicolas
    Margery, Jacques
    Assie, Jean-Baptiste
    Chouaid, Christos
    BIODRUGS, 2019, 33 (02) : 159 - 171
  • [48] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [49] Impact of adherence to National Comprehensive Cancer Network (NCCN)-recommended first-line therapy on treatment duration for patients with advanced non-squamous non-small cell lung cancer (NSCLC).
    John, Ani K.
    Yang, Baiyu
    Shah, Roma
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT OR PEMETREXED CONTINUATION MAINTENANCE TREATMENT IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A REPORT OF PATIENT SAFETY IN THE PARAMOUNT TRIAL
    De Marinis, Filippo
    Gridelli, Cesare
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Lois
    Molinier, Olivier
    Reck, Martin
    Sahoo, Tarini P.
    San Antonio, Belen
    John, William J.
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Visseren-Grul, Carla
    Paz-Arez, Luis G.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S842 - S843
12345